Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have...


Aegerion Pharmaceuticals (AEGR) may be up 200% YTD, but that doesn't mean the shares don't have more room to run, or so says Needham's Chad Messer who ups his price target to $100 from $50. "Assuming just 17% of [an] estimated 14K eligible patients are on treatment by 2018, we forecast worldwide Juxtapid sales of $590M, equating to AEGR EPS of $7.28," Messer notes. Slap a 30x multiple on that (which Messer justifies as "conservative" by referring to peers' multiples), apply a 25% discount, and you have yourself a $100 12-month PT.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs